St. Teresa Medical, Inc.

Nugyn, Inc.

Urometrics, Inc.

Alagin Research LLC

Curtis E Olson

Claire T Hovland

Philip A Messina

Jerome H Abrams

Paul Joseph Robinson

L Dean Knoll

Irwin Goldstein

Brian Jeffrey Jackson

Noel N Kim

Tim Floyd

Phil Messina

Apparatus, methods and systems for treating venous occlusive disease are provided. Generally, devices include a removable soft extension member that is adapted to be mounted at a proximal end of a therapeutic vacuum chamber. The soft extension member includes a proximal end composed of a tissue contacting portion configured to receive a tissue to be treated, and a distal end composed of a collar configured to be mounted onto an exterior surface of a vacuum chamber. Apparatus, methods and systems for increasing penile and cavernosal tumescence by application of a vacuum are also provided.

Apparatus and methods for treating venous occlusive disorders

Apparatus, methods and systems for treating venous occlusive disease are provided. Generally, devices include a soft extension member that is adapted to be mounted at a proximal end of a therapeutic vacuum device. The soft extension member includes a proximal end composed of a tissue contacting portion configured to receive a tissue to be treated, and a distal end composed of a collar configured to be mounted onto an exterior surface of a vacuum chamber. Apparatus, methods and systems for increasing clitoral and cavernosal tumescence by application of a vacuum are also provided.

A method of forming hemostatic sheets. Dextran and water are mixed to form a dextran-water mixture. The dextran-water mixture is formed into a first support layer. Fibrinogen and thrombin are mixed to form a fibrinogen and thrombin mixture. The fibrinogen and thrombin mixture is dispersed on the first support layer to form a hemostatic sheet.

Method of forming a hemostatic product

A method of inducing hemostasis in a wound. A hemostatic product is applied to a wound. The hemostatic product includes at least one hemostasis component. The hemostatic product is retained with respect to the wound by positioning a hydrogel material at least partially over the hemostatic product. At least a portion of the hemostatic product is dissolved. Hemostasis is induced in the wound with the at least one hemostasis component. The hydrogel material is separated from the wound. Substantially all of the hemostatic product remains on the wound.

Method of inducing hemostasis in a wound

A method of inducing hemostasis in a wound using a hemostatic product. A dextran support is provided. At least one hemostatic agent stabilizer is mixed with at least one hemostatic agent to form a hemostatic agent and stabilizer mixture. The at least one hemostatic agent includes at least one of thrombin and fibrinogen. The hemostatic agent and stabilizer mixture is associated with the dextran support. The hemostatic product is applied to the wound in which a bodily fluid is present. The at least one hemostatic agent is released from the hemostatic product to induce hemostasis in the wound.

A hemostatic product that includes a dextran support, at least one hemostatic agent and at least one hemostatic agent stabilizer. The at least one hemostatic agent is selected from the group consisting of thrombin and fibrinogen. The at least one hemostatic agent is associated with the dextran support. The at least one hemostatic agent stabilizer is associated with the at least one hemostatic agent.

Stabilizers for hemostatic products

A system for causing penile erection and/or subjecting the penis to stretching. The system utilizes a vacuum source and/or supply device, a housing configured to at least partially receive therein a penis, and a garment or support configured to retain and/or support the housing. Also disclosed is a method of using the system on a user's penis as discussed in the instant application.

System and method for treating and/or preventing erection problems

Therapeutic devices and methods according to embodiments of the invention alleviate e.g. urinary incontinence in female and male patients. Suction or vacuum, for example, is applied to the genital region, clitoris or clitoral region, the external urethral orifice, and/or other designated areas, e.g. physically stimulating the sacral/pudendal nerves and/or nerve roots and alleviating incontinence. Such embodiments also can encourage or cause clitoral engorgement, or otherwise promote blood flow in the genital region. Vacuum or suction applied to e.g. the clitoris creates a negative pressure in the clitoris that is lower than the systolic blood pressure, tending to promote engorgement of the clitoris with blood. Aspects of the invention are applicable not only to treatment of urinary and fecal incontinence, but also to the treatment of female sexual dysfunction. Aspects of the invention are also applicable to treatment of male incontinence and male erectile dysfunction.

Devices and methods for treatment of incontinence

Therapeutic devices and methods according to embodiments of the invention encourage or cause clitoral engorgement to assist in the treatment of female sexual dysfunction. A vacuum is created over the clitoris, or suction is applied to the clitoris, to create a negative pressure in the clitoris that is lower than the systolic blood pressure. This tends to promote engorgement of the clitoris with blood.

Clitoral treatment devices and methods

Devices and methods according to embodiments of the invention measure physiological changes that occur in the female during sexual arousal. These include changes in clitoral, vaginal-artery, and/or vaginal-capillary blood flow, clitoral engorgement, and bioimpedance, to name a few. Feedback devices and methods assist a patient or medical professional to determine when arousal occurs and what its best triggers are for a particular patient. Overnight arousal-event monitoring, or other continuous monitoring over extended periods of time, either at home or away from home, allows diagnosis of vasculogenic impairment or other problems. The effects of medicinal therapies aimed at female sexual dysfunction can be quantified and used to titrate proper dosages. Embodiments of the invention provide objective, quantifiable measures of multiple physiological variables associated with female arousal, in a manner heretofore unseen in the prior art.

Growing community of inventors

Saint Paul, MN, United States of America

Curtis E Olson